2578-7470

HIV Research & Clinical Practice

Informa UK (Taylor & Francis)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 171 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact171 DOIs
2

Add license metadata to 43 records

License metadata tells indexers and readers how each article may be reused.

Low impact43 DOIs
3

Attach ORCID iDs across 39 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact39 DOIs

DOIs for this ISSN

Showing the top 5 of 171 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 COVID-19 symptoms and SARS-CoV-2 infection among people livi… (10.1080/25787489.2020.1844521)
Abstract ORCID License
108.54 27
2 HIV and COVID-19: review of clinical course and outcomes (10.1080/25787489.2021.1975608)
Abstract ORCID
87.41 55
3 Identifying appropriate candidates for long-acting antiretro… (10.1080/25787489.2020.1824718)
Abstract ORCID License
85.96 13
4 Quality of life of older women living with HIV: comparative… (10.1080/15284336.2018.1554373)
Abstract ORCID License
83.55 12
5 Disengagement and reengagement of HIV continuum of care in a… (10.1080/15284336.2019.1595887)
Abstract ORCID License
78.10 10
6 Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a red… (10.1080/25787489.2020.1719319)
Abstract ORCID License
71.57 8
7 Ethical and practical considerations for mitigating risks to… (10.1080/25787489.2021.1902116)
Abstract License
70.75 25
8 Study protocol for the targeting effective analgesia in clin… (10.1080/15284336.2019.1627509)
Abstract License
65.05 19
9 Changes in central adipose tissue after switching to integra… (10.1080/25787489.2020.1848131)
Abstract License
63.94 18
10 Dolutegravir plus rilpivirine as dual regimen in virological… (10.1080/15284336.2019.1628460)
Abstract License
61.52 16
11 Vitamin D insufficiency is associated with subclinical ather… (10.1080/25787489.2020.1724749)
Abstract ORCID License
58.36 5
12 Parenting with HIV: a patient’s view on updated infant feedi… (10.1080/25787489.2024.2357871)
Abstract References ORCID
58.36 5
13 Reduced soluble CD14 levels after switching from a dual regi… (10.1080/25787489.2019.1653512)
Abstract License
57.31 13
14 Examining the association between stress and antiretroviral… (10.1080/25787489.2020.1763711)
Abstract License
57.31 13
15 A mobile health intervention in HIV primary care: supporting… (10.1080/25787489.2020.1862972)
Abstract License
57.31 13
16 Effects of atazanavir, darunavir, and raltegravir on fat and… (10.1080/25787489.2020.1809807)
Abstract License
55.70 12
17 Impact of the COVID-19 pandemic situation on HIV care in Liè… (10.1080/25787489.2021.1948773)
Abstract License
53.96 11
18 Comorbidity and polypharmacy among people with HIV stratifie… (10.1080/25787489.2024.2361176)
Abstract ORCID
53.96 11
19 Retention in clinical trials after prison release: results f… (10.1080/15284336.2019.1603433)
Abstract License
52.07 10
20 Effects of resistance training on muscle strength, body comp… (10.1080/25787489.2021.1975448)
Abstract License
52.07 10
21 Neurological manifestations in people living with HIV/AIDS i… (10.1080/25787489.2021.1975609)
Abstract License
52.07 10
22 96-week results of a dual therapy with darunavir/ritonavir p… (10.1080/25787489.2020.1734752)
Abstract License
47.71 8
23 A supervised exercise intervention fails to improve subjecti… (10.1080/25787489.2020.1839708)
Abstract License
47.71 8
24 Dolutegravir-based regimens in treatment-naive and treatment… (10.1080/25787489.2021.1941672)
Abstract ORCID
47.71 8
25 Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-… (10.1080/25787489.2021.1965757)
Abstract License
47.71 8
26 Impact of treatment adherence on efficacy of dolutegravir pl… (10.1080/25787489.2021.2016303)
Abstract ORCID
47.71 8
27 Successful recruitment of a multi-site international randomi… (10.1080/25787489.2020.1733794)
Abstract License
45.15 7
28 Effects of incentivizing viral suppression in previously inc… (10.1080/25787489.2020.1735816)
Abstract License
45.15 7
29 Impact of extended-release niacin on immune activation in HI… (10.1080/25787489.2020.1866846)
Abstract License
45.15 7
30 Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in… (10.1080/15284336.2019.1608714)
Abstract License
42.25 6
31 Developing a pilot lifestyle intervention to prevent cardiov… (10.1080/25787489.2021.1883957)
Abstract License
42.25 6
32 Effects of exercise training on bone mineral density in adul… (10.1080/25787489.2021.1979727)
Abstract License
42.25 6
33 “We are looking at the future right now”: community acceptab… (10.1080/25787489.2022.2054613)
Abstract ORCID
42.25 6
34 Characterization of low level viraemia in HIV-infected patie… (10.1080/25787489.2020.1716159)
Abstract License
38.91 5
35 Short-term aerobic training improves heart rate variability… (10.1080/25787489.2020.1810452)
Abstract License
38.91 5
36 Incidence of opportunistic infections and its predictors amo… (10.1080/25787489.2023.2187013)
Abstract ORCID
38.91 5
37 ‘The tablets make a certain noise’: uncovering barriers and… (10.1080/25787489.2024.2371174)
Abstract ORCID
38.91 5
38 Patient-reported tolerability and acceptability of cabotegra… (10.1080/25787489.2019.1661696)
Abstract
37.63 31
39 An individual community member’s perspective on HIV cure-rel… (10.1080/25787489.2023.2249690)
Abstract References
34.95 4
40 A closer look: factors impacting HIV durable viral suppressi… (10.1080/25787489.2024.2443886)
Abstract ORCID
34.95 4
41 Prevalence and predictors of virological failure among the p… (10.1080/25787489.2025.2490774)
Abstract ORCID
34.95 4
42 Increasing the meaningful involvement of women in HIV cure-r… (10.1080/25787489.2023.2246717)
Abstract
30.76 16
43 Participant experiences in HIV cure-directed trial with an e… (10.1080/25787489.2023.2267825)
Abstract
30.76 16
44 Presence of V72I, G123S and R127K Integrase Inhibitor polymo… (10.1080/25787489.2020.1734753)
Abstract License
30.10 3
45 Correlation between plasma glucose and hemoglobin A1c in HIV… (10.1080/25787489.2020.1766864)
Abstract License
30.10 3
46 Assessment of the HIV Enhanced Access Testing in the Emergen… (10.1080/25787489.2024.2403958)
Abstract ORCID
30.10 3
47 ‘With this study, we have hope that something is coming’: co… (10.1080/25787489.2023.2243046)
Abstract
29.40 14
48 Hypersensitivity reactions, hepatotoxicity, and other discon… (10.1080/25787489.2021.2003132)
Abstract
28.65 13
49 Participant experiences in a combination HIV cure-related tr… (10.1080/25787489.2024.2312318)
Abstract
28.65 13
50 Weight change with antiretroviral switch from integrase inhi… (10.1080/25787489.2024.2339576)
Abstract
28.65 13